TCA
ZOM

Transcend Capital Advisors’s Zomedica Corp. ZOM Stock Holding History

Transcend Capital Advisors’s Portfolio ZOM Stock Details ZOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,000
Closed -$2K – 404
2020
Q3 		$2K Buy
+20,000
New +$2.76K ﹤0.01% 269

Other funds holding ZOM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Transcend Capital Advisors's ZOM Position: Q4 2020 in Review

Transcend Capital Advisors sold out of Zomedica Corp. (ZOM) in Q4 2020, closing a stake of 20,000 shares — an estimated $2K sold.

Transcend Capital Advisors first reported a position in ZOM in Q3 2020 and held it in 1 quarter. The position peaked at $2K in Q3 2020. 38 funds tracked by Wall St. Rank hold ZOM as of Q4 2020.

  • Transcend Capital Advisors reported no remaining Zomedica Corp. position as of Q4 2020 after selling out during the quarter.
  • Transcend Capital Advisors sold 20,000 Zomedica Corp. shares in Q4 2020, an estimated $2K.
  • Transcend Capital Advisors first reported a position in Zomedica Corp. in Q3 2020 and held it in 1 quarter.
  • Transcend Capital Advisors's Zomedica Corp. position peaked at $2K in Q3 2020.
  • 38 funds tracked by Wall St. Rank held Zomedica Corp. as of Q4 2020.

Based on Transcend Capital Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.